News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

World’s largest radiology AI marketplace CARPL raises $6m to accelerate the adoption of AI in clinical workflows

CARPL

As people live longer and as emphasis on early detection of disease increases, there is a mounting burden on the healthcare services industry globally. This is being especially felt in radiology teams who are witnessing an acute shortage of radiologists. Currently, there are over 200 companies building applications using AI to automate parts of the radiologists’ work to bridge this talent gap. Today CARPL, an enterprise imaging AI marketplace platform, is announcing a $6m funding round to enable healthcare providers to access, assess and integrate these radiology AI applications into their clinical workflows through a single user-interface, single data channel and single procurement system. The seed funding round was led by Stellaris Venture Partners, a leading enterprise software investor, with participation from strategic angel investors* from Novo Holdings, Leapfrog PE, Bain & Co, Boston Consulting Group, UnitedHealth Group among others. CARPL will use the fresh funds to expand the team in North America and continue to build its tech stack. With more than 700 US-FDA approved AI applications, healthcare providers grapple with navigating the complex landscape of niche AI solutions. The daunting task involves determining the best AI solution for them and their patients, then seamlessly integrating it in the radiologists' workflows. This complexity has resulted in the sluggish pace of AI adoption in healthcare. A recent joint statement by the world’s top radiology associations also brings to light the importance of validation, deployment and monitoring of AI while being used in clinical practice. CARPL’s technology platform addresses this need using its proprietary DEV-D framework allowing healthcare providers to first Discover (D), Explore (E) and Validate (V) AI applications from CARPL’s AI marketplace, and subsequently Deploy (D) the most appropriate application across their clinical workflows. CARPL stands out as the only platform in the market with deep AI validation and monitoring capabilities, thereby ensuring safe and seamless AI deployment while upholding patient-centricity at its core. Additionally, CARPL’s universal AI viewer serves as a single user interface for radiologists, enabling them to accept, reject or refine AI outputs, which can subsequently be used to improve the performance of the AI itself. Operational since 2021, CARPL was founded by Vidur Mahajan, a physician with an MBA from the Wharton School of Business who has spent more than 12 years in the diagnostics industry. CARPL’s leadership comprises Dr Vasanth Venugopal as Chief Medical Officer, Rohit Takhar as CTO and most recently Dhruv Sahai as COO. CARPL has also ramped up its advisory team with the appointment of Dr Vijay Rao, SVP of Enterprise Imaging at Jefferson Health and a past-President of the Radiology Society of North America. “Over the past two years, we have onboarded more than 50 AI developers having 100+ AI applications, which made us the largest AI marketplace in terms of number of AI applications offered to customers. We are proud that some of the largest healthcare enterprises in the world have vetted our technology and trust us to be their partner in their AI and automation journeys.” said Dr Vidur Mahajan, CEO of CARPL. Drawing parallels with the lab medicine industry, Vidur Mahajan added: “We are democratizing radiology in the same way that automation and robotics revolutionized lab medicine, where a single pathologist signs out thousands of tests each day. We envision a future where CARPL creates ‘super-radiologists’ - AI-enabled radiologists who are ten times more productive than traditional radiologists.” Vidur Mahajan brings deep domain expertise having previously grown revenue 10x to $20m in 10 years at his family business Mahajan Imaging, a leading radiology service provider. He conceptualized CARPL under the guidance of his father Dr Harsh Mahajan, a pioneer in radiology, while working on validation and deployment of AI at Mahajan Imaging. CARPL comprises a multidisciplinary team with clinicians, scientists, engineers and business experts, all working towards the singular goal of driving exponential health outcomes using the encapsulated value of the entire AI ecosystem with the ultimate aim of ensuring access of quality diagnostics to patients. CARPL has more than 120 papers and conference presentations to its credit, and has coined some seminal concepts in clinical AI such as algorithmic audits, clinical explainability failure and unboxing AI. CARPL’s technology platform is used by the world’s top healthcare organizations like the Singapore Government, Massachusetts General Hospital (Boston), Radiology Partners (Los Angeles), University Hospitals (Cleveland), I-MED Radiology (Australia), Albert Einstein Hospital (São Paulo), Clinton Health Access Initiative, to name a few. CARPL is also creating impact in the public health space by working with the Government of India to enable large scale Tuberculosis Screening Programmes in the most remote regions of the country. As the global disease burden increases, owing to aging populations, early detection of disease and an increase in chronic/lifestyle diseases, the need for radiology services will increase, which increases the need for AI-assistance and automation in the delivery of these services. The global healthcare AI market is expected to cross $170 billion by 2029, of which almost $20 billion will be in the domain of radiology. Today, of the about 700 AI-based applications which are approved by the US-FDA, 80% are related to radiology. This number is expected to grow exponentially as access to training data and computation power becomes cheaper and easier to access. Alok Goyal, Partner at Stellaris Venture Partners commented: “The volume of imaging scans show a steady 9% year-on-year growth, outpacing the growth in the number of radiologists at a mere 1.8%. Bridging this demand gap is a crucial challenge for healthcare providers, and we believe AI will be the key. CARPL's integrated platform, designed for testing, deploying, and monitoring radiology AI applications, is poised to empower healthcare providers by seamlessly integrating AI into their clinical workflows. We are thrilled to join forces with Vidur and his team on this transformative journey.” As it becomes easier to build AI, the number and nature of AI applications used by doctors to deliver healthcare will increase exponentially. A platform approach that builds on connecting these AI developers to healthcare providers is the only way to exponentially improve the access, affordability and quality of care delivered today. CARPL is a new layer in the healthcare CIO’s stack that enables seamless access to the entire AI and analytics ecosystem through a single integrated platform. About CARPL CARPL is democratizing access to high quality healthcare by connecting AI applications and healthcare providers, exponentially improving the access, affordability and quality of medical care. CARPL enterprise imaging AI platform provides a single user-interface, data channel and procurement system for healthcare providers to access, assess, integrate and buy radiology AI applications in a safe and seamless manner. CARPL was incubated at Mahajan Imaging & Labs, India’s largest radiology service provider, as its technology division focused on building scalable clinical tools for AI validation, deployment and monitoring, under the guidance of Dr Harsh Mahajan, a pioneer in the field of radiology. For more information please visit https://carpl.ai About Stellaris Venture Partners Stellaris is an early-stage tech-focused VC firm that partners with fearless founders who dream big, think differently, and have an unstoppable desire to challenge the status quo. The fund works with these teams at nascent stages to help transform their ideas into resilient businesses. Stellaris does so with a team of seasoned, diverse operators and entrepreneurs who bring significant experience in building businesses and by providing access to some of the most successful founders and professionals. Since its inception in 2017, Stellaris has backed many market leaders such as Mamaearth, Whatfix, Propelld, Turno, Rigi, and others. For more information on Stellaris Venture Partners, visit https://www.stellarisvp.com Contact Details CARPL Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://carpl.ai/

February 01, 2024 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

The Best AI Girl Generator Apps You Must Try 2024

Summit Ventures BV

In today's technologically driven world, AI girl generator apps have gained immense popularity for their ability to create virtual AI companions. With a plethora of options available, we've curated a list of top-notch AI girl generator tools that you should explore in 2024. These applications offer innovative AI girl generation capabilities, providing unique and engaging experiences. Table of Featured AI Girl Generators 1. Introduction to AI Generated Girls 2. Featured AI Girl Generator Tools 2.1 GPTGirlfriend.online 2.2 GlamGirls.ai 2.3 ChaiApp.pro 2.4 AI-Girlfriend.co 2.5 AI-Companion.co 3. Frequently Asked Questions 4. Conclusion Top Five AI Girl Generator Apps The world of AI girl generators has seen significant growth, offering a variety of engaging options. While each application brings its unique features to the table, GPTGirlfriend.online stands out with its exceptionally engaging interactions and a wide range of capabilities. Girlfriend GPT: Your Gateway to AI Generated Girls Girlfriend GPT is an innovative AI-powered tool that brings your favorite AI girl characters to life, offering interactive experiences. This platform provides a wide array of activities, enabling you to create a virtual space for engaging conversations with your AI girl companion. Moreover, GPTGirlfriend.online offers unrestricted content for a diverse experience. Key Features: Empowers you to create your personalized AI girl companion. Allows unrestricted interactions and conversations. Offers affordable premium and deluxe subscription plans. Resumes conversations with long-term memory. Glam Girls AI: Generate your AI Girl in Seconds Glam Girls is renowned for having the best AI generated girls in the space. This platform is designed for those interested in crafting glamorous AI characters. Whether you're looking for AI girls with a sense of style or unique personalities, GlamGirls.ai has you covered. Key Features: Multiple scenarios for AI girl generation. Customizable interface to align with your preferences. Accommodates various interests and preferences in AI girl characters. Chai App: Create AI Girls for NSFW AI Images Chai App offers an intuitive platform for generating AI girls and companions, particularly suited for NSFW AI image generation. This application excels in providing realistic AI chatbot interactions and customization options for your AI girl companions. Key Features: Intuitive navigation for an immersive experience. Realistic chatbot interactions. Allows customization of AI girl companions. Features advanced capabilities for generating AI girls. AI Girlfriend: Personalized AI Girlfriends for Engaging Conversations AI-Girlfriend.co is the perfect choice for those seeking personalized AI girlfriends. This platform allows you to tailor your AI girlfriend according to your preferences. AI-Girlfriend.co creates engaging and realistic interactions with your ideal AI girlfriend character. Key Features: Provides realistic AI companion interactions with varied emotions and backgrounds. Abundance of features available for diverse AI girlfriend interactions. Offers budget-friendly pricing for personalized AI girlfriends. AI Companion: Engage with AI waifus and husbands AI-Companion.co is known for its wide range of character options in the AI girl generator domain. This versatile platform accommodates various conversations and interactions with AI chatbots, offering personalized experiences. Key Features: Support for multiple languages, enhancing accessibility. Personalization options to tailor the chatbot according to individual preferences. Broad spectrum of interests and character types for diverse user needs. Frequently Asked Questions Q: What is an AI girl generator? A: An AI girl generator is a software application that uses artificial intelligence to create virtual AI girl characters for various purposes, such as entertainment, interaction, or chatbot companionship. Q: How do AI girl generators work? A: AI girl generators work by utilizing advanced algorithms and machine learning techniques to generate AI girl characters with customizable traits, personalities, and conversation capabilities. Q: Can a AI girl generator be used for NSFW content? A: Some AI generated girls are designed to cater to NSFW (Not Safe For Work) content, offering options for more mature and adult-themed interactions. However, not all AI girl generator apps support explicit content. Q: Can I customize AI girl characters generated by these tools? A: Yes, most AI girl generator apps allow users to customize AI girl characters by selecting specific traits, appearances, and personalities to create personalized virtual companions. Q: Are there age restrictions for using AI girl generators? A: Yes, to use AI girl generators, users typically need to be at least 18 years old, as these tools may generate content that is intended for adults. Conclusion In the realm of technology, AI generated girls offer a gateway to interactive virtual companionship. These tools have transformed how we connect with AI characters, providing endless entertainment and personal interactions. Whether you seek customizable AI girls, engaging AI girlfriends, or glamorous AI characters, these apps cater to diverse preferences. They bridge the virtual and real worlds, offering a glimpse into the potential of AI companions. This guide has highlighted top AI girl generator apps in 2024, each with unique features. Some may include NSFW content, so choose accordingly. AI girlfriend apps pioneer technological innovation, enabling users to create, personalize, and interact with AI characters. Explore these apps for a distinctive experience in the world of AI companionship. Unlock the potential of AI girl generators today. GPTGirlfriend.online is the most advanced AI companion subscription service with a community of more than 1,000,000 Monthly Active Users. With more than 25,000 characters, it has transformed how people interact with and experience AI. Please refer to our detailed Terms of Use and Community Guidelines for comprehensive information on usage, safety, and ethical considerations on GPTGirlfriend.online Contact Details GPTGirlfriend Business hello@enias.io Company Website https://www.gptgirlfriend.online

February 01, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

University of Dayton Law School Leads the Way in Contract Excellence with the Adoption of the NCMA Contract Management Standard™

National Contract Management Association

The University of Dayton School of Law (UDSL) proudly announces its commitment to advancing education in Government Contracting & Procurement through the adoption of the National Contract Management Association's (NCMA) ANSI-approved Contract Management Standard™ (CMS™) and Contract Management Book of Knowledge ® (CMBOK ® ). The Master in the Study of Law (M.S.L.) in Government Contracting & Procurement program at UDSL is dedicated to providing students with the highest quality education and ensuring they are equipped with the knowledge and skills necessary for success in the ever-evolving profession of contract management. By incorporating the NCMA CMS™ and CMBOK ® into its program and course curricula, UDSL reaffirms its commitment to academic excellence and aligns with contract management best practices. Kraig Conrad, CEO of the National Contract Management Association, expressed enthusiasm about the partnership, stating, "We commend the University of Dayton School of Law for taking this progressive step for their program. This standard is a recognized benchmark in the profession, and its incorporation into UDSL's program reflects the university's dedication to providing students with a competitive edge in their careers." The NCMA CMS™ and CMBOK ® will serve as the foundation for UDSL's M.S.L. program, guiding the development of curriculum that addresses the dynamic and complex landscape of government contracting and procurement. This strategic adoption ensures that students receive comprehensive and up-to-date education and prepares them for success in the workforce. In response to the adoption, Sabra Tomb, UDSL’s Director of Training Programs and Strategic Business Development stated, "UDSL’s Government Contracting & Procurement Program is committed to delivering excellence in education and preparing our students to excel in their professional pursuits. The integration of the NCMA Contract Management Standard™ into our program is a testament to our dedication to providing a top-notch education that meets the needs of the industry and empowers our students for success." As UDSL continues to strengthen its position as a leader in legal education, this decision underscores its commitment to staying at the forefront of profession advancements and provide students with a competitive advantage in the job market. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. The School of Law offers a fully online master's program in government contracting and procurement designed by seasoned industry and government experts. The program is designed for contract professionals; a law degree is not required. Courses are taught in real-time to encourage active learning and provide opportunities for live feedback and interaction between faculty and students. Each class meets once a week, scheduled for working professionals. Financial aid, military, and veteran benefits; and corporate and government tuition deferment, assistance and reimbursement options are available. For more visit: https://udayton.edu/law/. Contact Details National Contract Management Association Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

February 01, 2024 05:00 AM Eastern Standard Time

Article thumbnail News Release

Cortland Biomedical Expands Cutting-Edge Capabilities and Capacity for Design and Development of Woven Biomedical Textile Structures

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, proudly announces the expansion of its weaving capabilities with the incorporation of two additional Jacquard Looms. This strategic move not only enhances the company's capacities, but also opens new avenues for groundbreaking advancements in medical textiles. Cortland Biomedical, in collaboration with global leaders in weaving equipment, integrates cutting-edge technologies into its machinery, ensuring excellence in every aspect from contact surfaces to yarn tensioning systems. Specializing in plain and narrow weave fabrics, including shuttle and rapier weaving, Cortland Biomedical excels in creating unique three-dimensional structures for applications like vascular grafts. These woven textiles, specifically designed for vascular and abdominal aortic aneurysm grafts and ensure limited blood flow. In addition, these woven textiles prove invaluable in orthopedics for bone and soft tissue repair, combining high strength with flexibility. Cortland Biomedical’s expertise positions it as a premier provider of tailored woven textile solutions for diverse medical applications. The addition of the two Jacquard Looms signifies a leap forward in Cortland Biomedical’s capabilities. This cutting-edge technology allows for unlimited possibilities in fabric design. Manipulating individual warp ends enables the creation of intricate structures, including bifurcations, convergences, tapers, and multi-layered fabrics. The fully electronic Jacquard loom offers unparalleled flexibility in altering fabric structures and patterns, significantly reducing material and time during prototyping. “Agility, curiosity, and credibility are at the heart of our mission, and set us apart as the easy-to-work-with partner our customers can count on to meet their unique medical device needs,” said Eric Brown, general manager, Cortland Biomedical. “Aligned with this strategy, our decision to add these Jacquard Looms was driven by our commitment to expanding capabilities, meeting the growing demands of the medical device industry, and fostering maximum innovation for our customers.” These looms boast the ability to weave thoracic size tubular grafts up to 46mm in diameter, create bifurcated structures as well as tapered flat and tubular structures, and generate infinite pattern designs through computer programming. With electronic let-offs designed for managing fine denier yarns, these looms can weave structures with high density and low permeability using polyesters, aramids, resorbables, and other fibers prominent in the medical device space. Cortland Biomedical will be exhibiting in booth 815 next week at MD&M West in Anaheim, CA. Eric and other company representatives will be on hand to discuss not only the company’s enhanced weaving abilities, but also its collaborative design and engineering processes, and capabilities for knitting, braiding and post-processing. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details SVM Public Relations Jordan Bouclin +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 31, 2024 10:00 AM Eastern Standard Time

Article thumbnail News Release

PathAI launches six additional oncology indications for PathExplore, an AI-powered pathology panel for spatial analysis of the tumor microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of six additional oncology indications for PathExplore™, the world’s first structured, standardized and scalable panel for characterization of the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). The additional indications are ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. PathExplore first launched in April 2023 with 8 indications, including non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic cancers. With this expansion, PathExplore human interpretable features (HIFs) will now be available across 14 oncology indications to accelerate the next phase of precision oncology. The last decade has seen significant strides in oncology drug development, but challenges remain – many cancer patients do not respond to available treatments, and many aren’t eligible for potentially transformative therapies because of a lack of actionable biomarkers. Distinct cell populations, tissue structures, and their spatial distributions across the TME represent some of the most promising areas of oncology research, however; traditional approaches are unable to access the full resolution of histopathology data at scale. “Pathology is the only data modality to define and quantify morphological changes resulting from treatment or disease progression,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “PathExplore enables researchers and drug developers to effortlessly investigate standard characteristics of the TME, such as the abundance of tumor-infiltrating lymphocytes, as well as spatial characteristics that were previously impossible to measure such as the ratio of lymphocytes to fibroblasts near the epithelial-stromal interface.” Since launch, PathExplore has established itself as the gold-standard in AI-powered digital pathology for oncology drug development. PathAI has partnered with over 50 pharma, biotech, academic, and laboratory partners to analyze >150,000 WSIs, resulting in 50+ publications and presentations. “PathExplore represents a tremendous leap forward in biological research, bypassing long standing constraints of many existing modalities by combining the widespread availability of H&E with the unprecedented resolution of AI,” said Mike Montalto, PhD, chief scientific officer at PathAI. “By expanding the availability of PathExplore’s structured pathology data into new disease areas, we’re empowering drug developers to continue to uncover insights that go beyond existing biomarkers.” To learn more about PathExplore, download our ebook that highlights real-world applications of AI-powered pathology solutions including PathExplore, in various stages of drug development programs. PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of pathology samples to improve efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

January 30, 2024 10:00 AM Eastern Standard Time

Article thumbnail News Release

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002

Benzinga

By Jeremy Golden, Benzinga Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the second and third leading causes of cancer death, respectively. Pancreatic and colorectal cancers are often Kirsten rat sarcoma (KRAS) mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. KRAS mutations are among the most prevalent human cancers. For these cancers, caused by a mutation of the KRAS gene, clinical-stage biotechnology company Elicio Therapeutics Inc. (NASDAQ: ELTX) is developing a pipeline of novel immunotherapies for treatment. Founded in 2011, Elicio Therapeutics has developed an innovative pipeline of cancer immunotherapies addressing critical unmet needs. Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008. Elicio’s lead clinical program, ELI-002, is a structurally novel investigational AMP therapeutic immunotherapy targeting mutant KRAS-driven cancers. It was designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors. ELI-002 2P has been studied in a phase 1 dose-escalation study in patients with high relapse risk mKRAS-driven solid tumors, following surgery and chemotherapy. After early findings from AMPLIFY-201 were released, ELI-002 was the subject of a publication in Nature Medicine. The paper — “ Lymph Node Targeted, mKRAS-specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The phase 1 AMPLIFY-201 Trial ” — details expanded and updated results that point to the power of Elicio Therapeutics’ use of precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against solid tumors. Originally presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2023 AACR Special Conference on Pancreatic Cancer, the data detailed in the publication is as of September 6, 2023. It is based on 25 patients with solid tumors (20 pancreatic, 5 colorectal) who were positive for minimal residual mKRAS disease after locoregional treatment. “When tumor DNA or protein persists or recurs after treatment, patients with pancreatic and colorectal cancers are unfortunately not left with many options and are often incurable,” said study author Shubham Pant, M.D., Associate Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. “These are promising early findings from the AMPLIFY-201 study with follow up ongoing. Most patients reduced their tumor biomarkers with some having complete clearance following treatment with ELI-002.” “The lymph node-targeted cancer vaccine candidate induced direct ex vivo mKRAS-specific T cell responses in 84% of patients, with 59% of patients demonstrating a response with two key types of T cells: helper cells and killer cells,” according to Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development, and Chief Medical Officer. “Past studies have not produced this large a fraction of patient response, this high a magnitude of a response or the expansion of both key populations of T cells,” he said. “Importantly, these T cell responses were specific to tumor-driver mutant KRAS neoantigens, correlated with reduced risk of relapse and we saw a pool of memory T cells form that we believe hold promise to confer long-term protection,” Haqq said. “We look forward to progressing ELI-002 into a randomized phase 2 trial as a monotherapy for patients with PDAC.” ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations, thereby increasing the potential patient population for ELI-002 and possibly reducing the chance of bypass resistance mechanisms. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 30, 2024 08:10 AM Eastern Standard Time

Article thumbnail News Release

New Task Force Sets Bold Goal of Achieving 60K Transplants by 2026

United Network for Organ Sharing

Today, the OPTN Expeditious Task Force announced a bold goal of achieving 60,000 successful, lifesaving deceased donor transplants annually in the U.S. by the end of 2026. That number represents a 58% increase in deceased donor transplants over the next three years. United Network for Organ Sharing (UNOS) is the non-profit organization that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN). The task force was created to pursue transformational changes across the nation’s organ donation and transplant system, increasing the number of lifesaving transplants, improving how donor organs are allocated, and increasing the use of all available organs. Members include transplant recipients, patient and donor family members, organ donation and transplant clinicians, community advocates and others, representing the many diverse perspectives of the national system. Twenty percent of task force members have no prior affiliation with the OPTN. “As the task force name implies, we need to move quicker, be more responsive, and deliver results for the patients we serve,” said Dianne LaPointe Rudow, DNP, president of the OPTN Board of Directors. “The reality is that while the number of transplants continues to grow, so does the non-use of available organs and allocations of organs out of the intended sequence of offers. Increasing transplantation to meet this bold aim is certainly a challenge. But we believe it is achievable with shared commitment to innovation and improvement in the organ allocation and placement process. Of course, any approach to boost the number of transplants must also uphold our commitment to provide all patients the best and most equitable access to receiving a transplant.” The need for improving efficiency is clear. In the case of kidneys, the most transplanted organ, the number of kidneys recovered from deceased donors increased by 56 percent between 2018 to 2023. Yet the number of kidney transplants only increased by 44 percent, meaning that approximately one quarter of kidneys recovered were not transplanted. The task force began benchmarking and goal setting with an assessment of the top 20 percent of transplant programs by growth in transplant volume across the country. These institutions represent what is possible for growth in organ transplant and provide invaluable insights and effective practices in pursuit of the task force’s bold goal of 60,000 transplants by 2026. The task force plans to conduct rapid, small-scale trials of innovative approaches to increase organ usage and placement efficiency. George Surratt, a member of the OPTN Board of Directors and a patient serving on the Expeditious Task Force, recognizes the effort as an opportunity to drive important changes. “We have the chance with this task force to make a real difference for patients,” Surratt said. “I’ve been the person waiting for that call from my doctor letting me know that an organ was available; that call is life-changing. So I’m excited that our work here today and going forward will ensure that more patients receive that all-important call and that the gifts of generous donors save even more lives. My fellow task force members and I are here with open minds, a willingness to embrace new approaches, and an understanding that the nation’s patients are the driving force behind this effort. It’s an exciting and inspiring time to be engaged in this work.” The Health Resources and Services Administration (HRSA) supports the task force’s work, and both HRSA and the Scientific Registry of Transplant Recipients (SRTR) contractor continue to provide feedback and ideas to shape the aims and approaches the task force is considering. The task force has reviewed recommendations from many sources, including the National Academies of Science, Engineering, and Medicine’s (NASEM) 2022 report and the work of the OPTN Ad Hoc Committee on Systems Performance. It also has received and continues to receive input from a variety of stakeholders, including patients, donor families, advocates, medical professionals and transplant leaders. As the task force develops actionable recommendations for new initiatives, it will remain engaged with stakeholders and the general public to guide its critical work. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

January 26, 2024 11:17 AM Eastern Standard Time

Article thumbnail News Release

InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need

Benzinga

By Meg Flippin, Benzinga Cannabinoids are having a moment in treating everything from Alzheimer’s to ocular diseases and InMed Pharmaceuticals Inc. (NASDAQ: INM) seems to be at the center of it all. The leader in cannabinoids and cannabinoid analogs pharmaceutical research, development, manufacturing and commercialization hit key milestones in advancing its cannabinoids-based treatments for Alzheimer’s disease, age-related macular degeneration (AMD) and epidermolysis bullosa in 2023 with more inroads to come in 2024. Take Alzehimer’s for starters. The disease is a big and growing problem afflicting about 6.7 million people 65 and older in the U.S. By 2060 it’s projected that 14 million people in the U.S. will suffer from the degenerative neurological disease. Treatments exist to address the symptoms related to memory and cognitive function and in some instances slow the rate of cognitive decline, but none have been able to reverse disease effects. Making An Impact InMed hopes to change that with INM-901, a rare cannabinoid analog the company says has the potential to target several biological pathways associated with Alzheimer’s. Previous industry research has shown cannabinoids hold promise in not only slowing the progress of Alzheimer’s but potentially reversing its effects thanks to their neuroprotective and regenerative properties. InMed’s data from preclinical i n vivo studies released last year showed INM-901 improved cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function. INM-901 also displayed neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study. To further evaluate INM-901 in 2024, InMed has initiated longer-term, six-month preclinical studies in behavior models. At the same time, the company is gearing up to launch more advanced preclinical studies, encompassing drug distribution, metabolism, active pharmaceutical ingredients and drug product formulation/manufacturing. Cannabinoids Can Protect Eyes Another big disease InMed is going after is age-related macular degeneration or AMD, which is a common cause of vision loss and potential blindness in people over 50. Based on 2019 estimates, AMD afflicts 19.8 million people or 12.6% of Americans 40 and up. Globally it affects 35% of people 74 and older. As it stands, there is no cure for AMD although treatment can prevent or slow the progression of the disease. Left unchecked patients may lose central field vision in the affected eye within 24 months of disease onset. INM-089, InMed’s ocular program for AMD launched in November is showing promise in changing that. Preclinical studies showed the potential for the drug to preserve retinal function, proactively protect the retinal cells that are responsible for vision and enhance the thickness of the outer nuclear layer of the retina where photoreceptors are situated, InMed said. Coming off those positive results, InMed is engaged in advanced preclinical studies and drug product formulation work, and it plans to launch Investigational New Drug studies in mid-2024. The goal is to file an Investigational New Drug application with regulatory authorities in the first half of 2025. “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs,” said InMed CEO Eric A. Adams. “Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.” Dermatology Program Additionally, last year, the company successfully completed a phase 2 clinical trial in the treatment of epidermolysis bullosa or EB, a rare genetic skin disease marked by fragile skin that can lead to extensive blistering and wounding. Data from a phase 2 clinical trial of INM-755 showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone, warranting further development. InMed thinks INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments and is currently seeking partnerships for continued development. Supplier To All In addition to developing its own treatments, InMed is a key supplier of rare cannabinoids as ingredients to the health and wellness market. The company’s BayMedica unit focuses on being a low-cost/high-quality manufacturer of certain non-psychoactive rare cannabinoids and an ingredients supplier to brands within the health and wellness industry. In 2023, the company said the unit experienced “significant” year-over-year revenue growth, and it is making moves to capitalize on revenue-generating opportunities in 2024. To that end, BayMedica is embracing a distributor model to expand coverage across the U.S. InMed is betting consumer brands will use more rare cannabinoid ingredients in 2024 – and InMed will be ready to provide them. “BayMedica continues to drive robust year-over-year revenue growth. The foreseeable future looks promising for the health and wellness segment as demand for minor cannabinoid ingredients continues to gain momentum,” said Adams. Cannabinoids hold promise to treat and potentially cure several diseases. InMed seems to be at the forefront of these groundbreaking advances. If 2023 is any indication, investors may want to watch for more milestones out of InMed this year and beyond. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 26, 2024 08:40 AM Eastern Standard Time

Article thumbnail News Release

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology

Kadimastem

Ness Ziona, Israel, January 25 th 2024, Kadimastem (TASE: KDST), a well-known biotech company in the field of cellular therapy, which is in the clinical development stages of innovative products for the treatment of ALS and diabetes, announced today the publication of the peer-reviewed prestigious journal of Clinical Toxicology. The article describes the development and safety of the new off the shelf cryopreserved AstroRx cell product in toxicity studies. Intrathecal injection of both low dose of DMSO (vehicle control) used for cryopreservation of human astrocytes and the cryopreserved AstroRx® cell product demonstrated high safety profile in mice. Link to the article. The article details the important milestone achieved by the company in the development of cryopreserved AstroRx® off the shelf cell product that will be thawed and injected near the patient's bedside. The development of a cryopreserved cell therapy product would allow the completion of more accurate and longer sterility testing, the completion of potency results, simplify the process of manufacturing scaling, enable long term storage and transport and facilitate timing of therapy delivery to the patient. The Cryopreserved product will help secure the clinical objectives of the upcoming IND approved phase IIa clinical trial in 30 ALS patients. Kadimastem's AstroRx® cell product is an allogeneic cell-based product composed of healthy and functional human astrocytes derived from embryonic stem cells. AstroRx® acts through multiple mechanisms of action that increase the survival of neurons, such as removal of toxic excessive glutamate, reduce oxidative stress, secrete various neuroprotective factors, and act as an immunomodulator. Dr. Michal Izrael, Kadimastem's VP R&D says: “The new formulation of cryopreserved of the shelf AstroRx® cell product (“thaw and inject”) is of great importance for product commercialization as well as to the success of our upcoming phase II clinical study, as it permits coordination of cell administration with patient care and completion of safety and quality control testing before cell administration.” Asaf Shiloni, Kadimastem’s CEO says: “We would like to thank Kadimastem's dedicated team for achieving this significant milestone. We are very excited to move towards our next Phase IIa clinical study approved by the FDA, with the new off-the-shelf AstroRx® cell product which will be tested using repeated intrathecal injections of AstroRx® in ALS patients.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook Contact Details Asaf Shiloni CEO s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

January 25, 2024 08:24 AM Eastern Standard Time

Image
1 ... 2829303132 ... 201